Long-Term Utilization and Benefit of Luspatercept in Transfusion-Dependent, Erythropoiesis-Stimulating Agent-Refractory or -Intolerant Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts

Authors

Uwe Platzbecker
Valeria Santini
Rami S Komrokji
Amer M Zeidan
Guillermo Garcia-Manero
Rena Buckstein
Dimana Miteva
Karen Keeperman
Natalia Holot
Jose Alberto Nadal
Yinzhi Lai
Sadanand Vodala
Barbara Rosettani
Ana Carolina Giuseppi
Aylin Yucel
Pierre Fenaux

Language

English

Publication Date

11-1-2023

Journal

Leukemia

DOI

10.1038/s41375-023-02031-7

PMID

37752285

PMCID

PMC10624606

PubMedCentral® Posted Date

9-26-2023

PubMedCentral® Full Text Version

Post-print

Keywords

Humans, Hematinics, Erythropoiesis, Myelodysplastic Syndromes, Activin Receptors, Type II, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins

Published Open-Access

yes

Recommended Citation

Platzbecker, Uwe; Santini, Valeria; Komrokji, Rami S; et al., "Long-Term Utilization and Benefit of Luspatercept in Transfusion-Dependent, Erythropoiesis-Stimulating Agent-Refractory or -Intolerant Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts" (2023). Faculty, Staff and Student Publications. 5711.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5711